Company Overview of Mimetogen Pharmaceuticals Inc.
Mimetogen Pharmaceuticals Inc., a biotechnology company, engages in designing and developing small molecule drugs to treat dry eye, glaucoma, age-related macular degeneration, keratoconus, and retinitis pigmentosa. The company’s products mimic the effects of neurotrophin proteins that help to maintain the health and growth of cells and tissues found in the eye. It provides tyrosine kinase agonists that prevent neuronal death; small molecule tyrosine kinase receptor agonists, which stimulates mucin secretion from conunctival goblet cells; and small molecule neurotrophin mimetics that rescues retinal pigment epithelial cells from oxidative stress-induced apoptosis. The company was founded in 2...
1000 de La Gauchetière Street West
Montreal, QC H3B 5H4
Founded in 2004
Key Executives for Mimetogen Pharmaceuticals Inc.
Chief Financial Officer and Vice President of Finance
Senior Director - Drug Discovery
Senior Scientist - Medicinal Chemistry
Compensation as of Fiscal Year 2014.
Mimetogen Pharmaceuticals Inc. Key Developments
Mimetogen Pharmaceuticals Inc. Announces Initiation of a Phase 3 Clinical Trial with MIM-D3 to Treat Dry Eye Syndrome
Oct 10 13
Mimetogen Pharmaceuticals Inc. announced that the initial patients have been enrolled in the company's first pivotal Phase 3 clinical study of MIM-D3 ophthalmic solution for the treatment of dry eye syndrome. MIM-D3 is the first in a class of molecules called TrkA agonists. MIM-D3 stimulates the production of mucin, which plays a critical role in the protection and overall health of the ocular surface. Mucins are essential for lubrication; the removal of allergen, pathogens, and debris; and corneal epithelial healing to reduce ocular surface damage. In addition, MIM-D3 may have additional benefits than currently available dry eye therapies, including the potential to improve neural function, which may improve corneal sensitivity and integrity. The pivotal trial will further evaluate the safety and efficacy of MIM-D3 in the treatment of dry eye syndrome. Approximately 400 patients will be randomized to receive 1% MIM-D3 ophthalmic solution or placebo twice daily over an 8 week period. The primary endpoints of the study are corneal fluorescein staining score in the CAE(SM) and ocular dryness. The safety and comfort of MIM-D3 compared to placebo will also be evaluated.
Mimetogen Pharmaceuticals Inc. Presents at BIO-Europe 2012, Nov-12-2012
Sep 19 12
Mimetogen Pharmaceuticals Inc. Presents at BIO-Europe 2012, Nov-12-2012 . Venue: CCH Congress Center Hamburg, Am Dammtor / Marseiller Str, 20355 Hamburg, Germany.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries